Estriol concentrations in plasma of normal, non-pregnant women

Rotti, K.; Stevens, James D.; Watson, David J.; Longcope, Christopher

doi:10.1016/0039-128x(75)90045-8

Cited by 58 publications

(15 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, when 10 ml plasma was extracted the oestriol level measured in post-menopausal women was below 5 pg/ml. This is in accordance with Rotti et al (1975) who stated that unconjugated oestriol levels in post-meno¬ pausal women were 6.0 ±1.2 pg/ml (n = 8). Flood et al (1976) reported values from 3 to 11 pg/ml (n = 4).…”

Section: Discussionsupporting

confidence: 94%

Bioavailability of oestriol

Englund¹,

Elamsson

Johansson

1982

Acta Endocrinologica

View full text Add to dashboard Cite

A rapid radioimmunoassay, using a specific antiserum against oestriol (Oe3) was developed for the analyses of unconjugated oestriol in post-menopausal women before and after oral administration of oestriol.One ml plasma was extracted once with 10 ml diethyl ether and assayed without further purification. The plasma levels of oestriol in post-menopausal women appear to be below 5 pg/ml. When 10 ml plasma from a pool was assayed 2.9 pg/ml was found. When 1 ml was assayed from individual patients levels between 10\p=n-\20 pg was found, which was not different from the plasma blank. A rise in plasma oestriol was found already 15 min after oral administration of 6 mg or 12 mg oestriol (Ovesterin\s=r\). On the average there was a plasma oestriol peak after 45 min and then a gradual decrease to low levels within 3 to 4 h. It is concluded that oestriol is rapidly absorbed when administered orally. However, the duration of the plasma oestriol elevation is short. Oestriol is rapidly metabolized. The short elevation probably explains the weak oestrogenic effect exerted by oestriol when administered once a day as receptor affinity for oestriol is low.

show abstract

Section: Discussionsupporting

confidence: 94%

Bioavailability of oestriol

Englund¹,

Elamsson

Johansson

1982

Acta Endocrinologica

View full text Add to dashboard Cite

show abstract

“…However, despite the reported estrogen effect in the second half or in 4th-1st weeks of the menstrual cycle on the background breast parenchymal enhancement, the level of serum estrogen is not highest at that period. As we know, the level of estrogen rises in the 2nd week of the menstrual cycle and reaches a peak just before ovulation at the late 2nd week of the menstrual cycle (27)(28)(29)(30). In our study of dense breasts, the highest parenchymal enhancement at the 3rd week correlated well with the effect of estrogen peak at the end of the 2nd week, and the wide range of DE in the 2nd week also correlated well with the rising level of estrogen in the 2nd menstrual week.…”

Section: Discussionmentioning

confidence: 99%

Background parenchymal enhancement on breast MRI: Influence of menstrual cycle and breast composition

Kang

Han

et al. 2013

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…Genistein and equol concentrations were measured taking into account the recovery of an estriol-glucuronide internal control at a concentration of 2 nmol/ml (973 ng/ml) (23). Estriol recovery was 75% (CV 15.5%) in this series of 190 plasma samples, excluding 5 outliers.…”

Section: Methodsmentioning

confidence: 99%

Soy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial

Khan

Chatterton

Michel

et al. 2012

Cancer Prevention Research

148

128

View full text Add to dashboard Cite

Background Soy isoflavone consumption may protect against breast cancer development. We conducted a Phase IIB trial of soy isoflavone supplementation, to examine its effect on breast epithelial proliferation and other biomarkers in the healthy high risk breast. Methods 126 consented women underwent a random fine needle aspiration (rFNA); those with ≥ 4000 epithelial cells were randomized to a double-blind six-month intervention of mixed soy isoflavones (PTIG-2535) or placebo, followed by repeat rFNA. Cells were examined for Ki-67 labeling index (Ki-67 LI), and atypia. Expression of 28 genes related to proliferation, apoptosis and estrogenic effect was measured using quantitative RT-PCR. Hormone and protein levels were measured in nipple aspirate fluid (NAF). All statistical tests were 2-sided. Results 98 women were evaluable for Ki-67 LI. In 49 treated women, the median Ki-67 LI was 1.18 at entry and 1.12 post-intervention, whereas in 49 placebo subjects it was 0.97 and 0.92 (p for between-group change 0.32). Menopausal stratification yielded similar results between groups, but within premenopausal soy-treated women, Ki-67 LI increased from 1.71 to 2.18 (p=0.04). We saw no treatment effect on cytologic atypia or NAF parameters. There were significant increases in the expression of 14/28 genes within the soy, but not the control group, without significant between-group differences. Plasma genistein values demonstrated excellent compliance. Conclusions A six-month intervention of mixed soy isoflavones in healthy, high risk adult western women did not reduce breast epithelial proliferation, suggesting a lack of efficacy for breast cancer prevention, and a possible adverse effect in premenopausal women.

show abstract

Estriol concentrations in plasma of normal, non-pregnant women

Cited by 58 publications

References 22 publications

Bioavailability of oestriol

Bioavailability of oestriol

Background parenchymal enhancement on breast MRI: Influence of menstrual cycle and breast composition

Soy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial

Contact Info

Product

Resources

About